The current average analyst rating on the shares is "buy", with 12 "strong buy" or "buy" recommendations, no "hold" and no "sell" or "strong sell" ratings.
The average consensus recommendation for the biotechnology and medical research peer group is "buy".
Wall Street's median 12-month price target for Maze Therapeutics, Inc. is $55.50, about 103.4% above its August 10 closing price of $27.28.
Higher R&D and G&A expenses
Maze said higher research and development expenses were mainly due to progression of MZE829 clinical development and increased personnel-related costs.
The company said higher general and administrative expenses were mainly due to increased personnel-related expenses and professional service costs.
Maze ended the second quarter with $495 million in cash after a $150 million equity raise.
The company expects HORIZON trial data for MZE829 in late 2026 or early 2027, and topline data from the CIPheR trial of MZE782 in PKU in 2027. Maze said it expects its cash runway to fund operations into 2029.
Q2 loss widens and misses estimates
Maze Therapeutics said its second-quarter net loss widened and missed analyst expectations, while second-quarter income from operations also missed analyst estimates.
The company reported a Q2 net loss of $44.73 million, compared with a consensus estimate of $42.42 million from 10 analysts. Q2 income from operations was -$48.04 million, versus an estimate of -$45.24 million from 10 analysts.
MAZE•
